CIDRAP: Peptilogics raises millions to fund trial for PJI treatment

Numerous media outlets reported on the AMR Action Fund’s participation in Peptilogics’ Series B2 financing round. AMR Action Fund CEO Henry Skinner talked with the Pittsburgh Business Times about the growing demand for hip, knee and shoulder replacements in the U.S., and the associated threat of prosthetic joint infections.

“There's an enormous amount of clinical need here and particularly as we think about the aging population, the number of hip, knee and shoulder replacements is growing very quickly,” he said. “We looked at it first from the patient standpoint and understand that there's a huge unmet medical need here. … This is a very challenging field but a huge need, and we're optimistic that our investments can really move the needle and drive a huge amount of patient benefit.”

CIDRAP also reported on the investment, including Skinner’s perspective on the threat of PJIs.

"Periprosthetic joint infections are a striking example of how antimicrobial resistance is rapidly undermining modern medicine," said AMR Action Fund CEO Henry Skinner, PhD. "The financial costs, diminished quality of life, and mortality associated with such infections are frankly unacceptable, and we are pleased to support the Peptilogics team as they advance zaloganan through the clinic and toward patients in need."

Read the Pittsburgh Business Times article.

Read the CIDRAP article.